CYTOO产品代理

产品分类 > 科研试剂 > CYTOO产品代理

CYTOO产品代理

具有生理相关细胞模型的下一代 HCS
“尽管前几年非常重视通过自动化和小型化来稳步提高筛选能力('数量增加'),而过去几年则更加重视内容和质量('质量增加')。今天,该领域的许多专家认为 HTS 处于十字路口,需要决定是更高的通量/更多的实验,还是更加关注具有更大生理相关性的分析,这两者都可能导致药物研发的更高生产力。”
CYTOO 的回答:质量和数量之间没有取舍
一般来说,复杂的组织模型比简单的 2D 或 3D 系统更可靠地反映体内情况。但是复杂度越高,吞吐量越低。复杂的模型还会带来其他问题,例如验证、再现性、图像分析、维护以及成本。
CYTOO 开创了通过使用微图案技术控制细胞微环境的能力。与大多数实验室和 CRO 使用的标准技术相比,CYTOO 培养平台显着增强了细胞模型的生理相关性。
CYTOO 的解决方案可以通过细胞微图案化(显示在恢复物理线索后调节基因组转录)将作为异质单层生长的传统细胞模型转化为更像体内的表型和形态。然后,这种独特的方法可以将可预测性差、稳健且低通量的检测简单转换为高度可靠且数据丰富的高内涵筛选工作。
价格: 0.00

Next   Generation HCS with physiologically relevant cellular models

“Whereas in previous years much emphasis has been put on a steady   increase in screening capacity ('quantitative increase') via automation and   miniaturization, the past years have seen a much greater emphasis on content   and quality ('qualitative increase'). Today, many experts in the field see   HTS at a crossroad with the need to decide on either higher throughput/more   experimentation or a greater focus on assays of greater physiological   relevance, both of which may lead to higher productivity in pharmaceutical   R&D.”

CYTOO’s answer: No trade   off between quality and quantity

In general,   complex tissue models reflect the in vivo situation more reliably than   simpler 2D or 3D systems. But the higher the complexity, the lower the   throughput. Complex models also raise other problems such as validation,   reproducibility, image analysis, maintenance, as well as costs.

   

CYTOO has pioneered the ability to control the cellular microenvironment through the use of micropattern technologies.  The CYTOO culture platform significantly 

enhances the   physiological relevance of cellular models in comparison to standard   techniques used by most labs and CRO’s.

   

CYTOO’s solutions can transform conventional cellular models grown as heterogeneous monolayers into a more in-vivo like phenotype and morphology through cell micropatterning (shown to modulate genomic transcription after restituting physical cues). The unique approach can then enable simple conversion of poorly predictable and robust, and low throughput assays, into highly reliable and data rich high content screening efforts.